Mirae Asset Global ETFs Holdings
KLRS

Mirae Asset Global ETFs Holdings’s Kalaris Therapeutics KLRS Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,132
Closed -$18.8K – 3208
2024
Q2 		$18.8K Buy
+1,132
New +$20K ﹤0.01% 2928

Other funds holding KLRS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.41M AUM 48.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's KLRS Position: Q3 2024 in Review

Mirae Asset Global ETFs Holdings sold out of Kalaris Therapeutics (KLRS) in Q3 2024, closing a stake of 1,132 shares — an estimated $18.8K sold.

Mirae Asset Global ETFs Holdings first reported a position in KLRS in Q2 2024 and held it in 1 quarter. The position peaked at $18.8K in Q2 2024. 59 funds tracked by Wall St. Rank hold KLRS as of Q3 2024.

  • Mirae Asset Global ETFs Holdings reported no remaining Kalaris Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Mirae Asset Global ETFs Holdings sold 1,132 Kalaris Therapeutics shares in Q3 2024, an estimated $18.8K.
  • Mirae Asset Global ETFs Holdings first reported a position in Kalaris Therapeutics in Q2 2024 and held it in 1 quarter.
  • Mirae Asset Global ETFs Holdings's Kalaris Therapeutics position peaked at $18.8K in Q2 2024.
  • 59 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q3 2024.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q3 2024, filed 14 Nov 2024.